cancer therapetics

Khalid Shah engineers stem cells to deliver cancer therapeutics directly to tumors, thereby increasing their efficacy.

The oncologist developed lifesaving childhood leukemia treatments and revolutionized chemotherapy.

Discover how scientists use multi-omic approaches to identify functional changes that lead to cancer cell drug resistance and devise new treatment strategies.

Spurred by family tragedy, the medical physicist wants to treat cancer in a new way.

The Harvard Medical School researcher’s work on the genetic basis of protein coding and production led him to make groundbreaking discoveries in immunology, molecular biology, and cancer genetics.

The company Cell Vault offers to hold consumers’ T cells for later use, but scientists suggest the service would benefit very few users.

Fly avatars bearing multiple genetic changes akin to those of a cancer patient lead to a tailor-made treatment that has shrunk the patient’s tumors.

See what cytokine activity and cellular starvation have to do with cancer metastasis.

In mice, cancer cells genetically modified to express an anticancer cytokine home to tumors and can reduce their growth. 

A hydroxylase inhibitor that prolongs the action of a gut-protective protein shows promise in mice as a treatment for radiation poisoning.

Experimental cancer therapeutics delivered to tumors via nanoparticles could provide a safer and more effective therapy than conventional chemotherapy.

Some notable quotes from this week’s meeting on cancer research

Researchers have genetically engineered a virus that is deadly to chickens and found that it can kill prostate cancer in vitro.

Physicist-turned-oncologist Robert Austin argues that cancer is a natural consequence of our rapid evolution.

Researchers are taking advantage of small, transparent zebrafish embryos and larvae—and a special strain of see-through adults—to understand the development and spread of cancer.

Every member of the scientific review panel at Texas’s $3-billion cancer research funding agency has quit, citing concerns about a lack of proper peer review.

A small patient trial offers hope that cancer-killing viruses might be a viable therapy after all.

Using RNA viruses to silence genes could optimize tissue targeting while reducing toxicity.